Leukemic stem cell frequency: A strong biomarker for clinical outcome in acute myeloid leukemia

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Terwijn, Monique ^a   Zeijlemaker, Wendelien ^a   Kelder, Angèle ^a   Rutten, Arjo P ^a   Snel, Alexander N ^a   Scholten, Willemijn J ^a   Pabst, Thomas ^b   Verhoef, Gregor ^c   Löwenberg, Bob ^d   Zweegman, Sonja ^a   Ossenkoppele, Gert J ^a   Schuurhuis, Gerrit J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD34 ANTIGEN; CD38 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STEM CELL; CANCER SURVIVAL; CANCER THERAPY; CELL COUNT; CELL DIFFERENTIATION; CELL FUNCTION; CELL POPULATION; CONTROLLED STUDY; FLOW CYTOMETRY; FOLLOW UP; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; TUMOR ENGRAFTMENT; ADOLESCENT; ANIMAL; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; ANTIGENS, CD34; ANTIGENS, CD38; BIOLOGICAL MARKERS; CELL COUNT; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; MICE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; PROGNOSIS; YOUNG ADULT;

EID: 84907278352     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107587     Document Type: Article

References (40)

1. Valent P, Bonnet D, De MR, Lapidot T, Copland M, et al. (2012) Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 12: 767-775.
2. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, et al. (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645-648.
3. Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature medicine 3: 730-737.
4. Dick JE (2008) Stem cell concepts renew cancer research. Blood 112: 4793-4807.
5. Taussig DC, Vargaftig J, Miraki-Moud F, Griessinger E, Sharrock K, et al. (2010) Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood 115: 1976-1984.
6. Moshaver B, Van Rhenen A, Kelder A, Van der Pol M, Terwijn M, et al. (2008) Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. Stem cells 26: 3059-3067.
7. Pearce DJ, Taussig D, Simpson C, Allen K, Rohatiner AZ, et al. (2012) Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem cells 23: 752-760.
8. Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, et al. (2001) A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 98: 1166-1173.
9. Feuring-Buske M, Hogge DE (2001) Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34(+)CD38(-) progenitor cells from patients with acute myeloid leukemia. Blood 9: 3882-3889.
10. Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, et al. (2008) Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 112: 568-575.
11. Sarry JE, Murphy K, Perry R, Sanchez P V, Secreto A, et al. (2011) Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rgammac-deficient mice. J Clin Invest 121: 384-395.
12. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, et al. (2009) CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138: 286-299.
13. Van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, et al. (2005) High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clinical cancer research 11: 6520-6527.
14. Ran D, Schubert M, Taubert I, Eckstein V, Bellos F, et al. (2012) Heterogeneity of leukemia stem cell candidates at diagnosis of acute myeloid leukemia and their clinical significance. Experimental hematology 40: 155-165.
15. Witte KE, Ahlers J, Schafer I, Andre M, Kerst G, et al. (2011) High proportion of leukemic stem cells at diagnosis is correlated with unfavorable prognosis in childhood acute myeloid leukemia. Pediatr Hematol Oncol 28: 91-99.
16. Roshal M, Chien S, Othus M, Wood BL, Fang M, et al. (2013) The proportion of CD34(+)CD38(low or neg) myeloblasts, but not side population frequency, predicts initial response to induction therapy in patients with newly diagnosed acute myeloid leukemia. Leukemia 27: 728-731.
17. Vergez F, Green AS, Tamburini J, Sarry JE, Gaillard B, et al. (2011) High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica 96: 1792-1798.
18. Van Rhenen A, Van Dongen GA, Kelder A, Rombouts EJ, Feller N, et al. (2007) The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. Blood 110: 2659-2666.
19. Van Rhenen A, Moshaver B, Kelder A, Feller N, Nieuwint AW, et al. (2007) Aberrant marker expression patterns on the CD34+ CD38- stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission. Leukemia 21: 1700-1707.
20. Becker MW, Jordan CT (2011) Leukemia stem cells in 2010: current understanding and future directions. Blood Rev25: 75-81.
21. Costello RT, Mallet F, Gaugler B, Sainty D, Arnoulet C, et al. (2000) Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res 60: 4403-4411.
22. Taussig DC, Pearce DJ, Simpson C, Rohatiner AZ, Lister TA, et al. (2005) Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 106: 4086-4092.
23. Feller N, Van der Pol MA, van Stijn A, Weijers GW, Westra AH, et al. (2004) MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 18: 1380-1390.
24. Terwijn M, Van Putten WLJ, Kelder A, Van der Velden VHJ, Brooimans RA, et al. (2013) High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/ SAKK AML 42A Study. Journal of clinical oncology 31: 3889-3897.
25. Bakker AB, Van den Oudenrijn S, Bakker AQ, Feller N, van Meijer M, et al. (2004) C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res 64: 8443-8450.
26. Van der Pol MA, Feller N, Roseboom M, Moshaver B, Westra G, et al. (2006) Assessment of the normal or leukemic nature of CD34+ cells in acute myeloid leukemia with low percentages of CD34 cells. Haematologica 88: 983-993.
27. Cloos J, Goemans BF, Hess CJ, Van Oostveen JW, Waisfisz Q, et al. (2006) Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia 20: 1217-1220.
28. Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, et al. (2011) Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer cell 19: 138-152.
29. Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, et al. (2011) Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci USA 108: 5009-5014.
30. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, et al. (2007) Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nature biotechnology 25: 1315-1321.
31. Bachas C, Schuurhuis GJ, Assaraf YG, Kwidama ZJ, Kelder A, et al. (2012) The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse. Leukemia 26: 1313-1320.
32. Buccisano F, Maurillo L, Del Principe MI, Del PG, Sconocchia G, et al. (2012) Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 119: 332-341.
33. Freeman SD, Virgo P, Couzens S, Grimwade D, Russell N, et al. (2013) Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol 31: 4123-4131.
34. Hosen N, Park CY, Tatsumi N, Oji Y, Sugiyama H, et al. (2007) CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci USA 104: 11008-11013.
35. Jordan CT (2002) Unique molecular and cellular features of acute myelogenous leukemia stem cells. Leukemia 16: 559-562.
36. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, et al. (2000) The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 14: 1777-1784.
37. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat med 12: 1167-1174.
38. Saito Y, Kitamura H, Hijikata A, Tomizawa-Murasawa M, Tanaka S, et al. (2010) Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med 2: 17ra9.
39. Ran D, Schubert M, Pietsch L, Taubert I, Wuchter P, et al. (2009) Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes. Exp Hematol 37: 1423-1434.
40. Cheung AMS, Wan TSK, Leung JCK, Chan LYY, Huang H, et al. (2007) Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia 2: 1423-1430.